New cell therapy targets Hard-to-Treat KRAS cancers
NCT ID NCT07396090
First seen Feb 12, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early study tests a new treatment called CAT-101, made from a patient's own immune cells (dendritic cells) loaded with a piece of the cancer-driving KRAS protein. It is given alone or with an immunotherapy drug (tislelizumab) to people with advanced pancreatic cancer or other solid tumors that have specific KRAS mutations. The goal is to see if the treatment is safe and can shrink tumors. Only 13 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.